HMN-214 is a prodrug of HMN-176 and is known to selectively interfere with PLK1 function. In the NB 3D spheroid tumor model, HMN-214 significantly and in a dose-dependent manner inhibits spheroid tumor mass and growth. Overall, our study highlights that targeting PLK1 using HMN-214 is a novel therapeutic approach for NB.

over 2 years ago

Journal

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CHEK2 (Checkpoint kinase 2) • PLK1 (Polo Like Kinase 1) • CHEK1 (Checkpoint kinase 1) • CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)

MYCN amplification

HMN-176 • HMN-214

over2years

Inhibition of PLK-1 by using a Small Molecule Inhibitor HMN-214 is a Novel Therapeutic Approach for High-risk Neuroblastoma. (PubMed, FASEB J)

Overall, our data highlights the role of PLK-1 in the oncogenic progression of NB and showed the efficacy of HMN-214 in inhibiting NB growth. Our future efforts will be directed towards elucidating the role of PLK-1 in NB and developing effective therapeutic strategies incorporating PLK-1 inhibitor.

over 2 years ago

Journal

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • PLK1 (Polo Like Kinase 1) • CDK1 (Cyclin-dependent kinase 1)

MYCN amplification

HMN-214